Ghrelin Agonist TZP‐101/Ulimorelin Accelerates Gastrointestinal Recovery Independently of Opioid Use and Surgery Type: Covariate Analysis of Phase 2 Data
Open Access
- 10 November 2011
- journal article
- research article
- Published by Wiley in World Journal of Surgery
- Vol. 36 (1), 39-45
- https://doi.org/10.1007/s00268-011-1335-9
Abstract
Background Delayed recovery of gastrointestinal (GI) motility is a common complication following surgery. TZP-101/ulimorelin is a macrocyclic peptidomimetic ghrelin receptor agonist with GI promotility effects that significantly accelerates time to recovery of GI motility compared to placebo following partial colectomy. It is also well tolerated. The objectives of this analysis were to identify predictors of GI motility recovery in patients undergoing partial colectomy and to evaluate whether these factors affect ulimorelin acceleration of GI recovery. Methods Covariate analysis assessed the effect of eight variables—age, sex, body mass index, type of surgery (right colectomy, left colectomy, other), duration of surgery, blood loss, total opioid consumption, country—on recovery of GI motility in 236 patients randomized to ulimorelin (n = 168) or placebo (n = 68). The primary endpoint was the recovery of GI function (time from the end of surgery to first bowel movement). Stepwise regression identified a parsimonious model of the smallest subset of variables best predicting GI recovery. Results Recovery was shorter for segmental/subtotal colectomies vs. right colectomies (P = 0.016) and longer with increased total opioid use (P = 0.037). The remaining variables had no statistically significant effect on GI recovery. Effects of ulimorelin 480 μg/kg (the most effective dose) on time to GI tract recovery remained statistically and clinically significant (hazard ratio = 1.81, P = 0.014) when adjusted for surgery type and/or total opioid use. Conclusions Two factors, type of surgery and total opioid use, independently modified times to recovery of GI motility following partial large bowel resection surgery. Acceleration of recovery of GI motility by ulimorelin was independent of these factors.Keywords
This publication has 27 references indexed in Scilit:
- Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled studyNeurogastroenterology & Motility, 2010
- Postoperative ileus: Impact of pharmacological treatment, laparoscopic surgery and enhanced recovery pathwaysWorld Journal of Gastroenterology, 2010
- Current therapies to shorten postoperative ileusCleveland Clinic Journal of Medicine, 2009
- Ghrelin receptor agonist (TZP‐101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesisAlimentary Pharmacology & Therapeutics, 2009
- Pathogenesis and Management of Postoperative IleusClinics in Colon and Rectal Surgery, 2009
- Ghrelin Agonist (TZP‐101): Safety, Pharmacokinetics and Pharmacodynamic Evaluation in Healthy Volunteers: A Phase I, First‐in‐Human StudyThe Journal of Clinical Pharmacology, 2008
- Patterns of Gastrointestinal Recovery after Bowel Resection and Total Abdominal Hysterectomy: Pooled Results from the Placebo Arms of Alvimopan Phase III North American Clinical TrialsJournal of the American College of Surgeons, 2007
- Prokinetic Effects of a New Ghrelin Receptor Agonist TZP-101 in a Rat Model of Postoperative IleusDigestive Diseases and Sciences, 2007
- Influence of ghrelin on interdigestive gastrointestinal motility in humansGut, 2006
- Is obesity a high-risk factor for laparoscopic colorectal surgery?Surgical Endoscopy, 2002